Elaine Chang

18PUBLICATIONS
69CO-AUTHORS
Molecular targetsMedical biotechnology not elsewhere classifiedCancer therapy (excl. chemotherapy and radiation therapy)PharmacogenomicsToxicology (incl. clinical toxicology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Aug 12, 2026
FDA Approval Summary: Erdafitinib for FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma.

|Aug 18, 2025
FDA Approval Summary: Nogapendekin Alfa Inbakicept-pmln with BCG for BCG-Unresponsive Carcinoma In Situ.

Brian L Heiss, Elaine Chang, Hee-Koung Joeng

|Sep 04, 2024
FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma.

Michael H Brave, William F Maguire, Chana Weinstock

|Aug 29, 2024
False-Positive Circulating Tumor DNA Results Do Not Explain Lack of Efficacy for PARP Inhibitors in Patients With Castration-Resistant Prostate Cancer Harboring ATM and CHEK2 Mutations.

Jaleh Fallah, Jianjin Xu, Hee-Koung Joeng

|Jul 01, 2024
RE: Is it time to reconsider the role of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma?

Jaleh Fallah, Haley Gittleman, Chana Weinstock

|Mar 15, 2024
Cytoreductive nephrectomy in the era of immune checkpoint inhibitors: a US Food and Drug Administration pooled analysis.

Jaleh Fallah, Haley Gittleman, Chana Weinstock

Pageof 3

Frequent Collaborators

8 joint publications

Laleh Amiri-Kordestani

7 joint publications

Richard Pazdur

6 joint publications

Shenghui Tang

6 joint publications

Paul G Kluetz